Paint Therapeutics
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Respiratory
Paint Therapeutics is a privately held biotechnology company developing Peptide-Drug Conjugates using their PulmoPaint™ platform technology. The PulmoPaint™ platform utilizes a surfactant-derived peptide to enhance lung residence time, improve local efficacy, and reduce systemic toxicity.
Company HQ City:
Atlanta
Company HQ State:
GA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
PT-0002
CEO
Bill Reddick
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
December 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}